John Vieceli, Ph.D., serves as Chief Product Officer at Quantum-Si Incorporated (NASDAQ: QSI), a pioneering company revolutionizing protein sequencing through semiconductor-based technology. Holding a Ph.D. in Applied Physics from Stanford University and a B.S. in Physics from the University of California, Berkeley, Dr. Vieceli brings over two decades of expertise in life sciences instrumentation and product development. His career began at Agilent Technologies, where he contributed to advancements in optical systems, before advancing to key roles in genomics at Affymetrix, focusing on GeneChip scanner technologies. At Illumina, Dr. Vieceli rose to Director of Product Management for sequencing systems, leading the development and launch of groundbreaking next-generation sequencing instruments that accelerated genomic research worldwide. His strategic vision drove multimillion-dollar product lines, enhancing throughput, accuracy, and accessibility in high-throughput sequencing. Notable achievements include spearheading cross-functional teams to deliver scalable solutions that powered major discoveries in personalized medicine and population genomics. In his current role at Quantum-Si, Dr. Vieceli oversees the end-to-end product strategy, from R&D to commercialization of the company's Proteo platform, aimed at enabling single-molecule protein sequencing at unprecedented scale and speed. Under his leadership, Quantum-Si has advanced toward routine protein analysis, positioning the company as a leader in proteomics and unlocking new frontiers in drug discovery, biomarker identification, and disease understanding.